


IN THE UNITED STATES PATENT AND TRADE MARK OFFICE

Applicants : Macquarie Research Limited; .
: Unisearch Limited
Serial No. : 09/367,009
Filed : November 8, 1999
Title : Diagnosis of disease using tears
Examiner : M. Davis
Group Art Unit : 1642

This is Annexure **B** referred to in my Declaration of


GARY COBON

Medical history of each (tear sample donor).


NO	AGE	SEX	CANCER TYPE	OTHER SITES	OTHER	RESPONSE	HORMONAL THERAPY	CURRENT CHEMO	NO OF CYCLES	PREVIOUS CHEMO	NO OF REGIMENS	ANALGESIA	CONCURRENT MEDS	CO DISEASES
2	61	F	Breast	Brain, Liver	Progressive disease. Brain mets for approx 10 years	Progressive disease	NI	Capecitabine	6	Cyclophos + Mit 6 Cycles, Weekly Tard 12	2	Paraloid NSAIDS	Analgesics: late schedule	Progressive disease. Brain mets
3	58	F	Breast	Lung, other	Progressive disease	Progressive disease	NI	Navelbine	11	CUF 14 Cycles, Mit 18 Tard 12	2	NI	Allopurinol, late schedule	Hypertension, diabetes, CVA, CVA, CVA
7	65	F	Breast	Brain	Metastatic bone disease 8 years	Progressive disease	Amifex	NI	17/12	NI	1	Paraloid	Allopurinol, late schedule	Hypertension, diabetes, CVA, CVA, CVA
11	46	F	Breast	Bone	Lobular carcinoma of breast. Brain mets for 8 years	Progressive disease	NI	NI	0	Adjuvant, late schedule 6 cycles, Cyclophos 75 cycles	2	Paraloid, NSAIDS, paraloid	Allopurinol, late schedule	Hypertension, diabetes, CVA, CVA, CVA
12	50	F	Breast	Lung, Liver	Adenocarcinoma of breast, post history of breast cancer	Stable disease	NI	NI	30 wks	Capodocine 18 cycles, Epilich 1 and 16	3	NI	Zinc, Mucosin, Tard 12	Lung metastasis, CVA, CVA, CVA
15	75	F	Breast	Liver	Post history of breast, post history of lung cancer	Progressive disease	NI	NI	2	2 cycles of late schedule	1	Paraloid	Allopurinol, late schedule	Cervical cancer, CVA, CVA, CVA
16	60	F	Breast	Bone	Ductal carcinoma breast	Stable disease	Amifex	NI	3	Upsonal, dorymucin X 8 cycles	1	NSAIDS, paraloid	Allopurinol, late schedule	diabetes
1	61	M	Colon	Liver	NI	NI	NI	Capecitabine, 6FU	7	NI	0	NI	Epilich, Xylgenin	Ischemic heart disease
5	69	M	Colon	Liver, Lung	Progressive disease	Progressive disease	NI	NI	0	NI	0	NI	NI	NI
13	55	M	Colon	Liver	Adenocarcinoma	Progressive disease	NI	Capecitabine, 6FU	7	5FU, Leucovorin, Pinosar 6 cycles	1	Paraloid	Dexamethasone, Mucosin, Tard 12	Oral Carcinoma, CVA, CVA, CVA
15	49	M	Colon	Liver	Progressive disease	Progressive disease	NI	Capecitabine, 6FU	2	NI	0	NI	NI	Adenocarcinoma
17	70	F	Colon	Liver	Stable disease	Stable disease	NI	Capecitabine, 6FU	3	NI	0	NI	NI	Adenocarcinoma
4	54	M	Lung	Lung, other	Progressive disease. Brain mets, adenocarcinoma, CVA, CVA	Progressive disease	NI	Capecitabine, Navelbine	4	NI	0	NI	Epilich, Xylgenin	SVT, Hypertension
6	77	M	Lung	NI	Adenocarcinoma of lung	Progressive disease	NI	Capecitabine	6	NI	0	NI	Dexamethasone, Mucosin, Tard 12	Hypertension
8	58	M	Lung	NI	Squamous cell carcinoma lung	Progressive disease	NI	NI	1	Capecitabine, Navelbine	3, 1	NI	NI	NI
9	40	M	Lung	Lung, other	Adenocarcinoma of lung, CVA, CVA, CVA	Progressive disease	NI	Capecitabine, Capecitabine	6	NI	0	NI	NI	NI
10	(MC)	F	Lung	NI	Lung cell carcinoma	Progressive disease	NI	NI	0	Tard 12, Navelbine 3 cycles	1	NI	Dexamethasone	NI
14	76	F	Lung	Lung	Lung primary	Progressive disease	NI	NI	0	Navelbine 6 cycles, Tard 12	1	NI	Allopurinol, late schedule	Kidney failure
18	67	F	Ovary	NI	Breast carcinoma, brain	Stable disease	NI	Capecitabine	8	Tard 12, Capecitabine X 6 cycles	1	NI	NI	NI
20	44	F	Ovary	NI	Breast carcinoma, brain	Stable disease	NI	Epilich	0	Tard 12, Capecitabine X 6 cycles	0	NI	NI	NI
21	50	F	Ovary	NI	Spinal papillary adenocarcinoma	Progressive disease	NI	NI	0	Tard 12, Capecitabine X 6 cycles	2	NI	NI	NI
22	73	M	Prostate	Bone	Adenocarcinoma prostate	Stable disease	NI	NI	0	NI	0	NI	NI	NI

IN THE UNITED STATES PATENT AND TRADE MARK OFFICE

Applicants : Macquarie Research Limited;
: Unisearch Limited
Serial No. : 09/367,009
Filed : November 8, 1999
Title : Diagnosis of disease using tears
Examiner : M. Davis
Group Art Unit : 1642

RECEIVED
MAR 20 2002
TECH CENTER 1600/2900

This is Annexure C referred to in my Declaration of



GARY COBON

RECEIVED
MAR 20 2002
TECH CENTER 1600/2900

Frequency of lacryglobin detection in tear samples		
Cancer Type	n	Frequency of lacryglobin detection in tears (% of subjects)
Breast cancer	8	88 %
Lung cancer	6	83 %
Colon cancer	5	100 %
Ovary cancer	3	33 %
Prostate cancer	1	100 %
Controls - no family history of cancer	3	33 %
Controls - family history of cancer	2	100 %